- Home
- SKX vs ROIV Comparison
SKX vs ROIV Comparison
Compare SKX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKX
- ROIV
- Stock Information
- Founded
- SKX 1992
- ROIV 2014
- Country
- SKX United States
- ROIV United Kingdom
- Employees
- SKX N/A
- ROIV N/A
- Industry
- SKX Shoe Manufacturing
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- SKX Consumer Discretionary
- ROIV Health Care
- Exchange
- SKX Nasdaq
- ROIV Nasdaq
- Market Cap
- SKX 6.9B
- ROIV 8.4B
- IPO Year
- SKX 1999
- ROIV N/A
- Fundamental
- Price
- SKX $62.18
- ROIV $10.67
- Analyst Decision
- SKX Buy
- ROIV Buy
- Analyst Count
- SKX 13
- ROIV 4
- Target Price
- SKX $70.33
- ROIV $17.50
- AVG Volume (30 Days)
- SKX 11.3M
- ROIV 5.9M
- Earning Date
- SKX 04-24-2025
- ROIV 05-29-2025
- Dividend Yield
- SKX N/A
- ROIV N/A
- EPS Growth
- SKX 9.64
- ROIV N/A
- EPS
- SKX 4.16
- ROIV N/A
- Revenue
- SKX $9,129,335,000.00
- ROIV $122,585,000.00
- Revenue This Year
- SKX $7.83
- ROIV N/A
- Revenue Next Year
- SKX $6.94
- ROIV N/A
- P/E Ratio
- SKX $14.93
- ROIV N/A
- Revenue Growth
- SKX 10.66
- ROIV 140.04
- 52 Week Low
- SKX $44.50
- ROIV $8.73
- 52 Week High
- SKX $78.85
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- SKX 69.08
- ROIV 47.82
- Support Level
- SKX $46.74
- ROIV $10.58
- Resistance Level
- SKX $61.70
- ROIV $11.77
- Average True Range (ATR)
- SKX 0.92
- ROIV 0.34
- MACD
- SKX 1.48
- ROIV -0.07
- Stochastic Oscillator
- SKX 97.98
- ROIV 7.56
About SKX Skechers U.S.A. Inc.
Skechers USA Inc is a lifestyle footwear company under the Skechers GO brand name. Products offered include various styles of women's shoes, men's shoes, girl's shoes, boy's shoes, performance shoes, and work shoes. Allied products offered are apparel, bags, eyewear, toys, and more. Its products are available for sale at department and specialty stores, athletic and independent retailers, boutiques, and internet retailers. The company's operating segments includes Wholesale and Direct-to-Consumer. It generates maximum revenue from the Wholesale segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.